Lupin signs exclusive agreement with Gan & Lee for Bofanglutide in India

 Lupin announced that it has entered into an exclusive License, Supply and Distribution agreement with Gan & Lee Pharmaceuticals, based in China, for Bofanglutide, a fortnightly GLP-1 receptor agonist.

Under the agreement, Lupin will have exclusive rights to commercialise and distribute Bofanglutide in India. The injection is administered once every two weeks and has been developed by Gan & Lee for the treatment of adults with type 2 diabetes and for weight management in individuals who are overweight or obese. Clinical data indicate that Bofanglutide reduces blood glucose levels and body weight, with outcomes reported to be comparable to or better than existing GLP-1 therapies, while following a fortnightly dosing schedule instead of a weekly regimen.

India has an estimated 174 million adults classified as overweight and around 50 million classified as obese. Diabetes affects approximately 90 million adults in the country. The agreement positions Lupin to expand access to Bofanglutide in the Indian market within these patient populations.

Nilesh Gupta, Managing Director, Lupin, said, “We are committed to offering the best solutions for managing chronic metabolic diseases like Diabetes, and addressing Obesity is one of the most urgent global health challenges. This partnership demonstrates our strategic focus on the GLP-1 class of drugs and highlights our dedication to delivering high-quality, innovative therapies for our patients.”

Rajeev Sibal, President – India Region Formulations, Lupin, said, “Bofanglutide offers a significant advantage with its convenient fortnightly dosing, thus reducing the number of injections by 50 per cent while delivering outcomes and clinically proven efficacy that matches or surpasses existing weekly formulations. This strategic alliance marks a pivotal step in strengthening Lupin’s leadership in metabolic health, expanding our innovative portfolio, and reaffirming our commitment to delivering transformative solutions.”

Gan & Lee Executive Vice President and Chief Commercial Officer Kai Du, along with Key Accounts Director Dr Dhaval Soneji, said, “On the heels of the Latin American exclusive agreement signed in November, this new partnership with Lupin for the Indian market further underscores Gan & Lee’s rapid global strategic advancement. Our goal is to provide superior treatment options for patients with metabolic diseases worldwide, while showcasing the value of Chinese biopharmaceutical innovation on the global stage.”

The post Lupin signs exclusive agreement with Gan & Lee for Bofanglutide in India appeared first on Express Pharma.